Skip to main content

Table 4 Extent of mono- and combination drug therapy use in the male BPO sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Monotherapy N % of monotherapy patients % of all patients in BPO sub-cohort % of all male patients
Any BPO drug monotherapy 29,739 100.0 81.9 61.1
Any alpha-blocker monotherapy 27,462 92.3 75.6 56.4
Any 5-ARI monotherapy 2277 7.7 6.3 4.7
Tamsulosin 21,158 71.1 58.3 43.5
Doxazosin 5456 18.3 15.0 11.2
Finasteride 2131 7.2 5.9 4.4
Alfuzosin 665 2.2 1.8 1.4
Dutasteride 146 0.5 0.4 0.3
Prazosin 101 0.3 0.3 0.2
Terazosin 44 0.1 0.1 0.1
Indoramin 38 0.1 0.1 0.1
Combination drug therapy N % of combination drug therapy patients % of all patients in BPO sub-cohort % of all male patients
Any combination drug therapy 6568 100.0 18.1 13.5
Any alpha-blocker + any 5-ARI 5573 84.9 15.3 11.4
Finasteride + tamsulosin 3262 49.7 9.0 6.7
Dutasteride + tamsulosin 1189 18.1 3.3 2.4
Doxazosin + tamsulosin 614 9.3 1.7 1.3
Doxazosin + finasteride 289 4.4 0.8 0.6
Alfuzosin + finasteride 233 3.5 0.6 0.5
Alfuzosin + tamsulosin 208 3.2 0.6 0.4
Doxazosin + finasteride + tamsulosin 167 2.5 0.5 0.3
Dutasteride + finasteride + tamsulosin 125 1.9 0.3 0.3
Other combinations 481 7.3 1.3 1.0
Drug class N % of all patients in BPO sub-cohort % of all male patients
Any BPO drug 36,307 100 74.6
Any alpha-blocker 33,984 93.6 69.8
Any 5-ARI 7896 21.7 16.2
  1. 5-ARI: 5-alpha reductase inhibitor; BPO: benign prostatic obstruction